Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JeRiCHO: ruxolitinib in relapsed or refractory classical Hodgkin lymphoma
2013-003369-33Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: Overall response rate after two cycles. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2013-003369-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003369-33.